Our clinical question is as follows: How can we better differentiate between true progression and pseudoprogression in patients with high PD-L1 NSCLC on pembrolizumab, especially when faced with acute mechanical complications such as esophageal obstruction? The gene discussed is CD274; the disease is non-small cell lung carcinoma.